摘要
目的探讨表柔比星配合多西他赛新辅助化疗对乳腺癌患者近远期疗效及细胞核增殖抗原(Ki-67)表达的影响。方法选取2017年1月至2018年2月山西白求恩医院乳腺外科收治的81例乳腺癌患者, 以随机数字表法分为两组, 对照组采用常规化疗方案为环磷酰胺+表柔比星+氟尿嘧啶, 观察组给予新辅助化疗方案为环磷酰胺+表柔比星+多西他赛。均化疗4个周期后, 比较两组疗效、不良反应、远期生存情况、Ki-67表达、血清肿瘤标志物。计量资料采用t检验, 计数数据采用χ2检验。结果观察组疾病缓解率75.6%明显高于对照组52.5%(χ^(2)=15.153, P<0.05);治疗后观察组Ki-67 mRNA、Ki-67蛋白表达明显低于对照组, 差异有统计学意义, 差异有统计学意义(t=0.392、0.191, P<0.05);治疗后观察组癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)表达明显低于对照组, 差异有统计学意义(t=0.041、0.043、0.077P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05);随访3年, 观察组复发率低于对照组, 差异有统计学意义(t=2.456、5.581、9.715, P<0.05), 组间侵袭性无病生存期(iDFS)、远处无病生存期(DDFS)、总生存期(OS)患者占比比较, 差异无统计学意义(t/χ^(2)值分别为1.372、0.115、0.167, P>0.05)。结论表柔比星配合多西他赛新辅助化疗在乳腺癌治疗中疗效确切, 安全性尚可, 能够调节Ki-67表达及血清肿瘤标志物水平, 延长远期生存期限。
Objective To investigate the effects of epirubicin combined with docetaxel neoadjuvant chemotherapy on short-term and long-term efficacy and expression of proliferation cell nuclear antigen(Ki-67)in breast cancer patients.Methods Totally,81 cases of breast cancer patients admitted to our hospital from January 2017 to Febrary 2018 were selected as samples,and were divided into two groups by random number table method.The control group received conventional chemotherapy regimen:cyclophosphamide+epirubicin+fluorouracil,and the observation group received neoadjuvant chemotherapy regimen:cyclophosphamide+epirubicin+docetaxel.After 4 cycles of chemotherapy,the efficacy,toxicities,long-term survival,Ki-67 expression and serum tumor markers were compared between the two groups.T test was used for the mean±standard deviation(±s)of measurement data,and χ^(2) test was used for counting data(n,%).The difference was statistically significant when P<0.05.Results The disease remission rate in observation group(75.6%)was significantly higher than that in control group(52.5%)(χ^(2)=15.153,P<0.05).After treatment,the expression of Ki-67 mRNA and protein in the observation group was significantly lower than that in the control group(t:0.392 and 0.191 respectively,P<0.05).After treatment,the expression of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 153(CA153)in the observation group was significantly lower than that in the control group(t=0.041,0.043 and 0.077 respectively,P<0.05).The incidence of toxicity and side effects was compared between the two groups(t=2.456,5.581 and 9.715 respectively,P>0.05).After 3 years of follow-up,the recurrence rate in observation group was lower than that in control group(P<0.05),and there was no significant difference in the proportion of invasive disease-free survival(iDFS),distant disease-free survival(DDFS)and overall survival(OS)between groups(t/χ^(2):1.372,0.115 and 0.167,respectivelyP>0.05).Conclusion Epirubicin combined with docetaxel neoadjuvant chemotherapy is effective and safe in the treatment of breast cancer,and can regulate the expression of Ki-67 and the level of tumor markers in serum,and prolong the long-term survival period.
作者
甄慧芬
潘丽慧
高晋南
郭繁
Zhen Huifen;Pan Lihui;Gao Jinnan;Guo Fan(Department of Breast Surgery,Shanxi Bethune Hospital,Shanxi Academy of Medical Science,Tongji Shanxi Hospital of Shanxi Medical University,Taiyuan 030032,China)
出处
《中华实验外科杂志》
CAS
北大核心
2022年第2期344-347,共4页
Chinese Journal of Experimental Surgery
关键词
表柔比星
多西他赛
乳腺癌
生存
不良反应
Epirubicin
Docetaxel
Breast cancer
Survival
Adverse reaction
